Idoxuridine

Drug Profile

Idoxuridine

Alternative Names: 2-Deoxy-5-iodouridine; 5-IDUR; 5-Iodo-2-deoxyuridine; 5-IUDR; Allergan 211; GF I115; IDU; IDUR; IdUrd; Iododeoxyuridine; IUDR; NSC 39661; SKF 14287

Latest Information Update: 20 Aug 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Unknown
  • Developer Nonindustrial source
  • Class Antineoplastics; Antivirals; Nucleosides; Radiosensitisers; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Colorectal cancer; Glioma

Most Recent Events

  • 04 Nov 1998 A preclinical study has been added to the pharmacodynamics section
  • 31 Oct 1997 Phase-II clinical trials for Colorectal cancer in USA (Unknown route)
  • 01 Dec 1994 Phase-II clinical trials for Glioma in USA (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top